There’s a weight loss injection blowing up in South America called Lipoless MD10, and yes—real doctors are prescribing it. So I did what I always do: I dug past the ads and the GLP-1 hype to figure out what it actually is. Lipoless MD10 is made by Laboratorio Edose in Paraguay, and the active ingredient is tirzepatide—the same molecule in Mounjaro and Zepbound. It’s a dual GLP-1/GIP receptor agonist, and the published trial numbers are insane: SURMOUNT-1 showed average weight loss around 19.5% at 10mg and up to 22.5% at 15mg. But here’s the part nobody wants to talk about: real-world use is messy. A retrospective analysis of FDA adverse event data found “incorrect dose administered” as the most reported issue linked to tirzepatide—19,461 reports, rising fast. That’s not the molecule “failing,” that’s a self-administration crisis, and Lipoless MD10 uses a manual syringe format where technique actually matters. Then you’ve got the 10mg reality check: roughly 46% GI side effects (mostly nausea/diarrhea), and SURMOUNT-4’s bombshell—82.5% of people who stopped regained at least 25% of their lost weight within a year. Translation: this isn’t a shortcut. Physician supervision isn’t optional—it’s the whole point.